Cornercap Investment Counsel Inc. Has $726,000 Position in United Therapeutics Co. (NASDAQ:UTHR)

Cornercap Investment Counsel Inc. cut its holdings in United Therapeutics Co. (NASDAQ:UTHR) by 61.6% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 2,027 shares of the biotechnology company’s stock after selling 3,257 shares during the quarter. Cornercap Investment Counsel Inc.’s holdings in United Therapeutics were worth $726,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of the business. ClariVest Asset Management LLC raised its stake in shares of United Therapeutics by 120.0% in the 2nd quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 42 shares during the period. V Square Quantitative Management LLC acquired a new stake in United Therapeutics in the 2nd quarter valued at approximately $30,000. Innealta Capital LLC bought a new stake in United Therapeutics in the 2nd quarter valued at approximately $33,000. USA Financial Formulas bought a new stake in United Therapeutics in the 3rd quarter valued at approximately $33,000. Finally, Capital Performance Advisors LLP acquired a new position in United Therapeutics during the 3rd quarter worth approximately $82,000. 94.08% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of analysts have recently commented on UTHR shares. LADENBURG THALM/SH SH boosted their price objective on shares of United Therapeutics from $319.00 to $344.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. Bank of America reduced their price objective on shares of United Therapeutics from $303.00 to $280.00 and set an “underperform” rating for the company in a research note on Thursday, August 1st. HC Wainwright lifted their target price on United Therapeutics from $400.00 to $425.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. Argus increased their price target on United Therapeutics from $360.00 to $400.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. Finally, Oppenheimer boosted their price target on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research report on Thursday, October 31st. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, United Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $370.86.

Insider Activity

In other news, CEO Martine A. Rothblatt sold 3,600 shares of United Therapeutics stock in a transaction that occurred on Monday, August 19th. The shares were sold at an average price of $344.18, for a total value of $1,239,048.00. Following the completion of the sale, the chief executive officer now directly owns 130 shares in the company, valued at approximately $44,743.40. The trade was a 96.51 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Nilda Mesa sold 224 shares of the business’s stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $412.28, for a total value of $92,350.72. Following the completion of the sale, the director now owns 5,783 shares of the company’s stock, valued at approximately $2,384,215.24. This trade represents a 3.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 113,396 shares of company stock valued at $42,175,418. 11.90% of the stock is owned by company insiders.

United Therapeutics Stock Down 6.0 %

United Therapeutics stock opened at $363.25 on Friday. United Therapeutics Co. has a twelve month low of $208.62 and a twelve month high of $417.82. The stock has a market cap of $16.22 billion, a P/E ratio of 15.95, a P/E/G ratio of 1.17 and a beta of 0.56. The company’s 50-day moving average price is $362.93 and its two-hundred day moving average price is $327.52.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, topping the consensus estimate of $6.16 by $0.23. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The business had revenue of $748.90 million during the quarter, compared to analysts’ expectations of $722.62 million. During the same period last year, the firm posted $5.38 EPS. The firm’s revenue for the quarter was up 22.9% compared to the same quarter last year. Equities analysts anticipate that United Therapeutics Co. will post 25.1 earnings per share for the current fiscal year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.